The purpose of seasonal infl uenza vaccination is to prevent its spread. The vaccines contain strains of the infl uenza virus recommended and approved for a particular season. Just like any other medicinal product, all vaccines require marketing approval. Batches of approved vaccines are extensively tested by the manufacturers and additionally controlled by the approving authorities, which issue the quality control certifi cates. This article not only to describes the legal background of quality control, but also how control test results obtained by a Croatian offi cial control laboratory are compared to manufacturer's results. We have found that testing results can slightly differ depending on methods/analytical procedures used in different laboratories. This investigation has also shown how important it is to test fi nished medicinal products, independently of testing at intermediate stages, and how retesting by control authorities ensures that marketed vaccines meet quality standards.
Influenza (flu) is an acute infectious disease caused by infl uenza viruses, which spreads quickly and has high morbidity. Infl uenza viruses belong to the family Orthomyxoviridae and are classifi ed according to their antigen differences (internal antigens) into types A, B, and C. Infl uenza viruses have two antigens (glycoproteins) on their surface: haemagglutinin (HA) and neuraminidase (NA). These surface antigens change rapidly and unpredictably, rendering the immune system vulnerable all over again every year. Changes are either large and are called shifts, which are rare, and minor, called drifts, which occur practically every year (1) . Repeated (seasonal) vaccination is the effective way to prevent the spread of the disease. Every year, World Health Organisation (WHO) issues an overview of the epidemiological state of the infl uenza virus worldwide, and recommends which predominant strains of types A and B should be used in vaccines for the coming season. Type C infl uenza is not included because it is far less frequent than A and B types and usually causes very mild respiratory symptoms or no symptoms at all. It does not cause epidemics and does not much burden public health.
Following the WHO recommendations, European Union (EU) experts decide which strains to use for the coming season, bearing in mind the epidemiological situation in the EU (2) (3) . Following this recommendation, vaccine manufacturers used reassorted strains that give high yields of required surface antigens (4) .
Seasonal infl uenza vaccines are sterile suspensions of strains of two types of infl uenza viruses -type A (subtypes H1N1 and H3N2) and type B. The vaccines are produced in such a way that the vaccine primarily contains the HA and NA antigens, without diminishing the antigenic characteristics of those antigens. The potency of the vaccine, i.e. the stated amount of the haemagglutinin antigen present in the vaccine per strain per dose is 15 micrograms (µg) unless clinical evidence supports the use of a different amount (4) . Neither the European Pharmacopoeia (4) nor the guidelines issued by the Committee for Proprietary Medicinal Products (CPMP) require defining the content of the neuraminidase antigen (2) .
In Croatia, 2009/2010 seasonal vaccination included two types of vaccines: surface antigen, inactivated, and split virion, inactivated, both approved by the Agency for Medicinal Products and Medical Devices (HALMED). Pursuant to the Medicinal Products Act (5), the same institution performs quality control of medicinal products prior to marketing. The purpose of quality control is to establish compliance with quality standards defi ned in marketing approval. A special form of quality control for immunological medicinal products and medicinal products derived from blood or plasma is conducted by both the manufacturer and independent authority, in Croatia's case by HALMED. Immunological medicinal product is a medicinal product that is or contains vaccine, toxin, serum or allergen (5, 6) .
In the European Union (EU), quality control is conducted by the Official Medicines Control Laboratory (OMCL), which is independent from the manufacturer, to ensure safety and quality of medicinal products in use (7, 8 1 The EDQM acts as the Secretariat for OCABR network activities, as mandated by the European Commission 2 The Member State contacts the marketing authorisation holder (MAH) to indicate a need for OCABR certifi cates for batches of a product on their market. Samples of the batch to be released are sent, along with production and control protocols, to an OMCL within the EC. If the results are satisfactory, the CA issues an 'Offi cial Control Authority Batch Release Certifi cate' to the MAH. This OCABR certifi cate means that the batch has been examined and tested by an OMCL, in accordance with the OCABR guidelines pertaining to the medicinal product, and is in compliance with the approved specifi cation laid down in the relevant monographs of the European Pharmacopoeia and in the relevant marketing authorisation (9) . haemagglutinin antigen concentration/identity, bacterial endotoxin content, while purity is tested on the fi rst fi ve lots of a monovalent bulk following the introduction of a new infl uenza strain (9, 10) .
In Croatia, each batch of an immunological medicinal product is subject to special (double) quality control, regardless of whether it has the OCABR certifi cate. The applicant must submit to HALMED suffi cient quantities of samples for analysis, manufacturer's certifi cate of analysis for the batch in question, manufacturer's production documentation, and quality control and the batch release certifi cate issued by the relevant agency in manufacturer's country or the EU. If requested, the applicant should also submit a suffi cient number of samples of the original raw materials and their test reports (6) . Before applying for independent quality control, the vaccine manufacturer has to perform tests on the intermediates and on the fi nished product. One of the tests on the fi nished product is potency testing, i.e. determining haemagglutinin antigen in the the vaccine fi lled in the primary containers. An other test the manufacturer performs only on the fi rst three monovalent pooled harvests from each working seed lot is the test for the presence and the type of neuraminidase (4, 10) .
In addition to other tests mentioned earlier, the control laboratory does the potency testing in the fi nished product, pursuant to the OCABR guidelines for infl uenza vaccines (10) . HALMED follows the same quality control procedure. However, time requirements are tight. Whenever WHO recommends a new strain to be included in the vaccine, manufacturing process for the new strain has to be revalidated and report submitted to regulatory authorities. In addition, the manufacturer has to obtain an international reagent specifi c to the selected strain to measure the concentration of each HA antigen (11) .
The objective of this article is to present special (double) quality control procedure and compare control test results to manufacturer's to see if there are and what are the causes of discrepancies.
MATERIALS AND METHODS

Samples
Samples of seasonal fl u vaccine (2009/2010) were tested in four laboratories. HALMED laboratory (Lab 1) and EU OMCL laboratory (Lab 2) tested two batches of the fi nished product (batches A and B) produced from the same fi nal bulk (FB) 3 and samples of that fi nal bulk. The manufacturer of the fi nished product (Lab 3) tested the same samples as Lab 1 and 2, while the manufacturer of the fi nal bulk (Lab 4) tested only the batch of the fi nal bulk All test results were delivered to HALMED. Table 1 shows all materials used for testing. The content of haemagglutinin antigens in infl uenza vaccines was tested using the single radial immunodiffusion (SRID) method, as described in the European Pharmacopeia (4) 4 . This method is not affected by purifi cation of surface antigens or virus dissociation used in vaccine production. Specifi city is achieved with specifi c antiserums, and can serve to compare two antigen preparations (14) . The method is based on passive diffusion of antigens into an agarose gel containing uniformly distributed antibodies. Upon the fi rst contact of the antigen with an antibody soluble complexes are formed, while with further penetration of the antigen through the agar, the concentration of the antigen drops. When the optimum concentration ratio of antigens and antibodies is obtained, an insoluble precipitation ring is formed, which is round 3 The fi nal bulk (FB) is produced by blending the necessary/appropriate quantities of monovalent pooled harvests (active compounds for each individual virus strain). Final bulk (FB) fi lled into the primary containers after labelling and packaging becomes Final product (4). 4 The SRID method is based on the method by Wood et al. (12) with several modifi cations. The method was fi rst used as a method for testing infl uenza vaccine value in 1978 (13). in shape (15) . This ring confirms the identity of vaccine antigen and it is measured to calculate (and therefore quantify) the content of HA in the vaccine. Each laboratory has its own standard operating procedure for the SRID method. Lab 1 followed the procedure of the manufacturer of the fi nished product. The agarose solution was prepared by adding an optimal quantity of specifi c antiserum in the volume necessary to precipitate individual virus strains 5 . The agarose/antiserum mixture was poured onto glass plates and allowed to cool. The plates were placed in a humid, dark chamber and left at +4 o C until the following day. Wells 4 mm in diameter were punched into the resulting gel for inoculation with 20 µL of the diluted reference antigen, i.e. vaccine sample.
Reagents and methods
Reference antigens were dissolved according to the NIBSC instructions and/or vaccine manufacturer's qualification report. A series of vaccine sample solutions and reference substances were prepared using Zwittergent 3-14 detergent and PBS in the appropriate dilutions for vaccine samples and reference antigens (1:1, 3:4, 1:2, and 1:4). The tested solutions were inoculated in triplicate and the reference substances in duplicate. The prepared plates were stored in a humid, dark chamber at room temperature for 24 hours to allow for diffusion of the antigen and reaction between the antigens and antibodies. The reaction was stopped by sinking the plate into a prepared 5 The quantity of each antiserum is stated on the antiserum certifi cate. The quantity of the necessary specifi c antiserum for obtaining sharp precipitation rings is established by the vaccine manufacturer in a series of preliminary tests for the fl u vaccine for the 2009/2010 season. solution, and the plates were left to dry. After drying, the plates were stained to make precipitation rings visible and destaining of the background made the rings appropriate for reading. The precipitation rings were measured using a glass magnifi er which magnifi es 7 times and antigen content was obtained following the procedure described by Williams (13) . The content of haemagglutinin antigen is calculated using the software program CombiStats v4.0, EDQM (16) .
RESULTS AND DISCUSSION
The specifi cations for haemagglutinin antigen content for all three strains of the infl uenza virus were taken from the European Pharmacopoeia. The declared content per strain for the fi nished product (fi nal lot) is 15 µg/dose and the lower limit is ≥12 µg/dose (4). Retesting followed HALMED's standard operating procedure. Table 2 Lab 2 tested the same batches of the fi nished product and of the fi nal bulk as did Labs 1 and 3. Table 3 There is a good agreement, with minor deviations, between Labs 1, 2, and 3. Lab 1 and 3 got the results that did not meet specifi cation and Lab 2 results were bordering on the lower limit for both the fi nal bulk and the fi nished product (Figure 1) .
Considering that the tests were conducted on immunological medicinal products, whose active substances are of biological origin, the results may show variations under different testing conditions, even if the same methods/analytical procedures are applied. The test results confi rm the importance of testing the fi nished product (fi nal lot) and not just the fi nal bulk, and the importance of testing batch samples by a control laboratory before marketing. 
Sažetak
PROVJERA KAKVOĆE CJEPIVA ZA SEZONSKU GRIPU Za prevenciju i suzbijanje širenja gripe kao zarazne bolesti svake se godine provodi sezonsko cijepljenje cjepivima koja u svom sastavu sadržavaju sojeve virusa infl uence preporučene i odobrene za tu sezonu. Da bi se mogla staviti u promet, sva cjepiva moraju od nadležnog tijela dobiti dozvolu za stavljanje u promet kao i drugi lijekovi. Puštanje u promet proizvedenih serija odobrenog cjepiva zahtijeva osim opsežnih ispitivanja od strane proizvođača i dodatnu kontrolu od strane nadležnog tijela koje izdaje Certifi kat o provedenoj provjeri kakvoće temeljem kojeg se cjepivo kao imunološki lijek može staviti u promet. Cilj ovog rada je prikazati ne samo pravnu osnovu provjere kakvoće već i kako su uspoređeni rezultati dobiveni ispitivanjem u hrvatskome kontrolnom laboratoriju u odnosu na rezultate ispitivanja proizvođača. Rezultati pokazuju da postoje manja neslaganja rezultata ispitivanja različitih laboratorija koja su u ovisnosti s korištenim metodama/analitičkim postupcima (sličan ili identičan analitički postupak). Rezultati također pokazuju važnost ispitivanja koja se provode na gotovom proizvodu, neovisno o ispitivanjima provedenim na međuproizvodima, kao i važnost retestiranja koje provodi nadležno tijelo u svrhu osiguranja da se na tržištu nalaze samo imunološki lijekovi koji udovoljavaju zahtjevima kakvoće. 
